National Institutes Of Health

An FDA panel today supported approval of olaparib as maintenance treatment for adults with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic cancer.

The Partnership for Aging and Cancer Research Program awarded seven grants intended to fund research into the link between aging and cancer.

Chimeric antigen receptor T-cell therapies have been approved by the FDA for two indications thus far, with a third for multiple myeloma expected sometime next year. James N. Kochenderfer, MD, a physician-scientist in the Surgery Branch of the National Cancer Institute, is one of the few people who can say they have been a part of CAR T-cell development in all three areas that have demonstrated historically high response rates among patients with advanced blood cancers.

Cancer incidence rates represent one key measure of progress in the fight against cancer, but they are not the only consideration. According to a special report published in The New England Journal of Medicine, concordance between incidence and mortality rates provides a more complete picture of cancer burden.

The NIH selected five scientists as Lasker Clinical Research Scholars.

William G. Cance, MD, has begun his new role as American Cancer Society’s chief medical and scientific officer.

A study by the NCI-sponsored SWOG Cancer Research Network showed nearly half of the network’s phase 3 clinical trials influenced clinical care guidelines or new drug approvals.

Hospitalized older patients with cancer demonstrated higher risk for malnutrition compared with their younger counterparts, according to results of a prospective Brazilian study published in Cancer.

An observational, prospective cohort study to discover new information about how HIV and herpes viruses interact with the immune system, with a goal of learning more about how T cells in the immune system respond to and fight off long-term (chronic) viruses, in order to improve medical care in the future.

Phase 1 study evaluating the safety and tolerability of genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen in patients with relapsed and/or refractory solid tumors (ACTengine IMA203-101)